Combining CD47 inhibitors with PD-1/PD-L1 inhibitors or cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitors may enhance the anti-tumor immune response by promoting T cell activation and reducing immune suppression in the TME [84]. This evidence concerns the gene CTLA4 and neoplasm.